Business risk concept

Barron’s writes:

Johnson & Johnson’s Covid-19 vaccine offers enormous promise as a pathway out of the worst of the pandemic. Delivered as a single dose, without the extreme storage requirements of the vaccines from Pfizer and Moderna, it could speed up global inoculation if it proves effective.

But on Wednesday, the New York Times reported that the company is facing delays in the manufacturing of the vaccine that have put it up to two months behind its initial production schedule. The report comes amid growing anticipation for data from Johnson & Johnson’s (ticker: JNJ) Phase 3 trial of the vaccine, expected in the coming weeks.

Speaking at J.P. Morgan’s health care investor conference on Monday, Johnson & Johnson CEO Alex Gorsky said that the company aimed to have “hundreds of millions of doses” of the vaccine available in the first half of this year, and “close to one billion” by the end of the year.

“We’re still on track to be able to achieve those volumes,” Gorsky said. “And again, we’re working night and day to see what else can we do to accelerate that even more in an effective and safe, compliant, high-quality manner.”

But according to Wednesday’s New York Times report, the company is falling behind on production pledges it made to the federal government’s Operation Warp Speed…

To read the full post, please click here.

Comment on this article

You must be logged in to post a comment.